Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Guillaume Herbreteau
Observed names:
G. Herbreteau,
Herbreteau, Guillaume
Institution:
Centre Hospitalier Universitaire de Nantes
Observed institutions:
Centre National de la Recherche Scientifique,
Inserm,
Centre Hospitalier Universitaire de Nantes,
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers,
Immunologie et Nouveaux Concepts en Immunothérapie,
Nantes Université
show all 6
ORCID:
0000-0003-3705-2114
Observed ORCID:
0000-0003-3705-2114
OpenAlex ID:
A5039404381
Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations
2021
·
Anne-Laure Bidaud
, Patrick Schwarz
, et al.
·
Journal of Fungi
·
114
PDF
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
2022
·
Gabriel Morin
, Caroline Degrugillier-Chopinet
, et al.
·
The Journal of Experimental Medicine
·
80
Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
2019
·
Guillaume Herbreteau
, Audrey Vallée
, et al.
·
Journal of Thoracic Disease
·
70
Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
2018
·
Guillaume Herbreteau
, Audrey Vallée
, et al.
·
Oncotarget
·
65
PDF
Persistent deficiency of circulating mucosal-associated invariant T (MAIT) cells in ANCA-associated vasculitis
2016
·
Cécile Braudeau
, Karine Amouriaux
, et al.
·
Journal of Autoimmunity
·
65
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
2020
·
Guillaume Herbreteau
, Alexandra Langlais
, et al.
·
Journal of Clinical Medicine
·
53
PDF
Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline
2016
·
Anne C. Knol
, Audrey Vallée
, et al.
·
Experimental Dermatology
·
41
Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non–small-cell Lung Cancer
2023
·
Laurent Mathiot
, Benoit Nigen
, et al.
·
Clinical Lung Cancer
·
35
PDF
Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study
2021
·
Guillaume Herbreteau
, Audrey Vallée
, et al.
·
Cancers
·
31
PDF
Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation
2015
·
Audrey Vallée
, Clarisse Audigier-Valette
, et al.
·
Lung Cancer
·
30
Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay
2019
·
Audrey Vallée
, Marie Denis-Musquer
, et al.
·
PLoS ONE
·
23
PDF
Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
2020
·
Guillaume Herbreteau
, Audrey Vallée
, et al.
·
Cancers
·
19
PDF
Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib
2024
·
Thomas Papazyan
, Marc G. Denis
, et al.
·
Targeted Oncology
·
13
Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis
2023
·
Benoit Nigen
, Thomas Goronflot
, et al.
·
Lung Cancer
·
12
PDF
Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
2023
·
Marc G. Denis
, Guillaume Herbreteau
, et al.
·
Translational Lung Cancer Research
·
11
PDF
Circulating tumour DNA: analytical aspects and clinical applications for metastatic melanoma patients
2017
·
Guillaume Herbreteau
, Audrey Vallée
, et al.
·
Annales de biologie clinique
·
11
HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature
2022
·
Laurent Mathiot
, Guillaume Herbreteau
, et al.
·
Current Oncology
·
9
PDF
Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid
2017
·
Sandrine Théoleyre
, Ingrid Masson
, et al.
·
Lung Cancer
·
9
Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report
2017
·
Gaelle Quéreux
, Guillaume Herbreteau
, et al.
·
BMC Research Notes
·
9
PDF
Use of Circulating Tumoral DNA to Guide Treatment for Metastatic Melanoma
2019
·
Guillaume Herbreteau
, Sandrine Charpentier
, et al.
·
Pharmacogenomics
·
8
Association between dementia and reduced walking ability and 30-day mortality in patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia
2017
·
G. Chapelet
, A. S. Boureau
, et al.
·
European Journal of Clinical Microbiology & Infectious Diseases
·
8
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study
2024
·
Marion Ferreira
, Aurélie Swalduz
, et al.
·
Lung Cancer
·
7
PDF
MEM: An Algorithm for the Reliable Detection of Microsatellite Instability (MSI) on a Small NGS Panel in Colorectal Cancer
2021
·
Guillaume Herbreteau
, Fabrice Airaud
, et al.
·
Cancers
·
7
PDF
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
2020
·
Baptiste Le Calvez
, Yannick Le Bris
, et al.
·
eJHaem
·
7
PDF
Rapid detection of amoxicillin-susceptible Escherichia coli in fresh uncultured urine: a new tool to limit the use of broad-spectrum empirical therapy of community-acquired pyelonephritis
2016
·
Guillaume Chapelet
, Stéphane Corvec
, et al.
·
International Journal of Antimicrobial Agents
·
4
Show more works
View as search
Works count:
46
Citation count:
752
H-index:
13
I10-index:
16
Year
Topic
Type